SCHEMBL1122875

SCHEMBL1122875

O=C(N[C@@H](Cc1ccc(OCc2ccccc2)cc1)C(=O)O)c1ccc(OCc2cccc(OCc3ccccc3)c2)cc1

nearest known ligand 0.79

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
GPR132 Q9UNW8 11/20 0.79
GPR34 Q9UPC5 3/20 0.66
PTPN1 P18031 2/20 0.66
CMKLR2 P46091 1/20 0.64
CMKLR1 Q99788 1/20 0.64
PPARG P37231 3/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27658925 1.00 GPR132 (0.79) GPR132GPR34PTPN1CMKLR2CMKLR1
SCHEMBL1122836 0.95 GPR132 (0.71) GPR132GPR34PTPN1CMKLR2CMKLR1
SCHEMBL1122846 0.95 GPR132 (0.71) GPR132GPR34PTPN1CMKLR2CMKLR1
SCHEMBL1123134 0.95 GPR132 (0.71) GPR132GPR34PTPN1CMKLR2CMKLR1
SCHEMBL1123234 0.95 GPR132 (0.71) GPR132GPR34PTPN1CMKLR2CMKLR1
SCHEMBL27638081 0.94 GPR132 (0.89) GPR132GPR34PTPN1CMKLR2CMKLR1
SCHEMBL1122680 0.94 GPR132 (0.89) GPR132GPR34PTPN1CMKLR2CMKLR1
SCHEMBL1123299 0.93 GPR132 (0.77) GPR132GPR34PTPN1PPARG
SCHEMBL1123033 0.93 GPR132 (0.77) GPR132GPR34PTPN1PPARG
SCHEMBL1123232 0.93 GPR132 (0.77) GPR132GPR34PTPN1PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1644321-B1 NEW BENZAMIDES AS PPATY MODULATORS S A L V A T LAB SA (ES) 2011-02-09 EP claimed
CN-1835914-A New benzamides as PPAR[upsilon] modulators S A L V A T LAB SA (ES) 2006-09-20 CN claimed
US-20060160894-A1 Benzamides as ppar modulators LABORATORIOS S.A.L.V.A.T.,S.A. (ES) 2006-07-20 US claimed
EP-1644321-A2 NEW BENZAMIDES AS PPATY MODULATORS LABORATORIOS S.A.L.V.A.T., S.A. (ES) 2006-04-12 EP claimed
WO-2004110983-A2 NEW BENZAMIDES AS PPARϒ MODULATORS LABORATORIOS S.A.L.V.A.T., S.A. (ES) 2004-12-23 WO claimed
EP-1644321-B1 NEW BENZAMIDES AS PPATY MODULATORS S A L V A T LAB SA (ES) 2011-02-09 EP disclosed
CN-1835914-A New benzamides as PPAR[upsilon] modulators S A L V A T LAB SA (ES) 2006-09-20 CN disclosed
US-20060160894-A1 Benzamides as ppar modulators LABORATORIOS S.A.L.V.A.T.,S.A. (ES) 2006-07-20 US disclosed
EP-1644321-A2 NEW BENZAMIDES AS PPATY MODULATORS LABORATORIOS S.A.L.V.A.T., S.A. (ES) 2006-04-12 EP disclosed
WO-2004110983-A2 NEW BENZAMIDES AS PPARϒ MODULATORS LABORATORIOS S.A.L.V.A.T., S.A. (ES) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160894-A1 Benzamides as ppar modulators PPARD, PPARA, PPARG GPR132 122/4885GPR34 166/4885PTPN1 2708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.